Clinical Trial Update: An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency [Phase 2]

View source ↗

Summary

An open-label Phase 2 study evaluates continuation treatment with a combination of pyrimidine nucleosides in patients with thymidine kinase 2 deficiency. The tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymidine Kinase Deficiency

Drugs mentioned

• Pyrimidine nucleosides (combination)

Snippet

Sponsor: UCB BIOSCIENCES, Inc. | Conditions: Thymidine Kinase 2 Deficiency | Phase 2 | Status: ACTIVE_NOT_RECRUITING